secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-09-10T11:05:24+00:00
Accession:  0001193125-26-387197
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint posts updated investor presentation with LUGANO Phase 3 data; specifics not disclosed in excerpt
--------------------------------------------------------------------------------

- EyePoint posted an updated investor presentation on September 10, 2026, on its website.
- Presentation titled 'LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses'.
- No specific efficacy, safety, or financial figures are included in the provided excerpt.
- DURAVYU is being studied for wet age-related macular degeneration in the LUGANO Phase 3 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/0001193125-26-387197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-20260910.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-387197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer